These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1329225)

  • 1. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16).
    Long BH
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):3-19. PubMed ID: 1329225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
    Kerrigan D; Pommier Y; Kohn KW
    NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
    Rappa G; Lorico A; Sartorelli AC
    Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
    Woynarowski JM; Sigmund RD; Beerman TA
    Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of podophyllotoxins.
    Imbert TF
    Biochimie; 1998 Mar; 80(3):207-22. PubMed ID: 9615861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of epipodophyllotoxin-induced thymocyte apoptosis: possible role of a novel Ca(2+)-independent protein kinase.
    Ye X; Georgoff I; Fleisher S; Coffman FD; Cohen S; Fresa KL
    Cell Immunol; 1993 Oct; 151(2):320-35. PubMed ID: 8402939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (etoposide and teniposide).
    Lönn U; Lönn S; Nylen U; Winblad G
    Cancer Res; 1989 Nov; 49(22):6202-7. PubMed ID: 2553248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26.
    Minocha A; Long BH
    Biochem Biophys Res Commun; 1984 Jul; 122(1):165-70. PubMed ID: 6331440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
    Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
    Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical pharmacology of etoposide and teniposide.
    Clark PI; Slevin ML
    Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA damage signals induction of fas ligand in tumor cells.
    Mo YY; Beck WT
    Mol Pharmacol; 1999 Feb; 55(2):216-22. PubMed ID: 9927611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
    Chen GL; Yang L; Rowe TC; Halligan BD; Tewey KM; Liu LF
    J Biol Chem; 1984 Nov; 259(21):13560-6. PubMed ID: 6092381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition.
    Chow KC; Macdonald TL; Ross WE
    Mol Pharmacol; 1988 Oct; 34(4):467-73. PubMed ID: 2845248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II.
    Liu M; Chen Y; Zhang L; Wang Q; Ma X; Li X; Xiang R; Zhu Y; Qin S; Yu Y; Jiang XC; Duan Y; Han J
    J Biol Chem; 2015 Jun; 290(23):14418-29. PubMed ID: 25914138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of VP-16 analogues.
    Long BH; Casazza AM
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S26-31. PubMed ID: 8070024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.
    Yang L; Rowe TC; Liu LF
    Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA topoisomerase II inhibitors.
    IARC Monogr Eval Carcinog Risks Hum; 2000; 76():175-344. PubMed ID: 11000976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.